% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • unbearibull unbearibull May 18, 2011 9:51 AM Flag

    jesse.livermore - interested in your opinion on ECTE

    re: scam

    First... Google this name... Dr. Robert Langer

    Dr. Langer holds over 700 issued or pending patents and is head of the Langer Lab at M.I.T. which is the largest bioengineering lab in the world. Dr. Langer has authored over 1100 scientific papers and is considered by many to be the world’s foremost authority on transdermal drug deilvery and tissue engineering.

    Dr. Langer’s wiki page...

    Dr. Langer is the Chairman of the Scientific Advisory Board for Echo and the inventor of the Prelude Skin Prep System - Echo has the exclusive license.

    some DD to check out...

    Interview with Dr. Langer … Dr. Langer discusses Echo Therapeutics Prelude™ SkinPrep device as well as their Symphony™ trandermal continuous glucose monitoring (tCGM) system.

    Echo Therapeutics' Needle-Free Symphony Continuous Glucose Monitoring System

    Scientific American - Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings - Echo Therapeutics is testing a biosensor system that reads glucose levels without breaking the skin.

    Uri Landesman of Platinum Partners (Hedge Fund) on Bloomberg Radio on ECTE (also check out his comments on Implant Sciences IMSC)

    ECTE.OB PR in

    ECTE.OB wins Federal Research Grant

    Uri Landesman on ECTE on Bloomberg Radio ( approx @ 7:20 )

    Uri Landesman on CNBC Squawkbox mentioning ECTE.OB (approx @ 2:00)

    M.I.T. Langer Lab

    Morgan Joseph research report

    JMP Securities research report

    Lifetech Capital research report

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • unbear...

      It is clear you have done a lot of research and I would be the last one to call this a "scam" mas I know virtually nothing about how they plan to do thjese things...but will try to find out...

      In the meantime my advice stands...If they can not explain what they are doing and language you can understand...Then be very careful...

      Regards...":>) JL

      • 1 Reply to jesse.livermore
      • Thanks JL... Thie best explanation I've found is from the Scientific American article...

        As the Prelude removes skin and hair that could interfere with the biosensor's reading, it passes tiny electric pulses into the skin, says Echo Therapeutics chairman and CEO Patrick Mooney. Based on the response to these pulses, the Prelude can determine when it has reached live underlying skin cells that allow the biosensor to provide a more accurate reading. The patient then applies the disk-shaped biosensor to the patch of skin prepped by the Prelude. The membrane on the biosensor's surface detects glucose as it diffuses out of the body's capillaries. The sensor contains an enzyme that reacts with the glucose and relays the indication as an electric signal. The impulse passes wirelessly to a handheld device, which records the information and monitors the readings. Each sensor can be used for two days before being replaced by a fresh one, and then either used in the same spot or another Prelude-treated location.

        Tufts Medical Center in Boston spent several years as a clinical site testing Echo's Symphony tCGM. "We frequently during surgery take blood samples for instantaneous testing" of blood glucose levels, regardless of whether the patient is diabetic, says Michael England, the center's chief of adult cardiac anesthesia. Continuous monitoring is particularly important during surgery because patient insulin levels vary. "Regular insulin we give people during surgery could take 45 minutes to an hour to take effect," he says.

        England co-authored (along with three Echo researchers) a July 2008 study in the Journal of Diabetes Science and Technology indicating the accuracy of Symphony's blood glucose measurements was comparable with the more common practice of drawing and testing blood samples. This finding was consistent with the results of a Symphony tCGM study that Echo announced in November. Using about 900 Symphony tCGM glucose readings paired with reference blood glucose measurements (taken using blood samples), Echo claimed its technology was 97 percent accurate.

2.10+0.13(+6.60%)3:19 PMEDT